Market Access Strategy
EUROPEAN ROADMAP TO MARKET ACCESS IN NON-HODGKIN LYMPHOMA (NHL)
Drug: potential new treatment of relapsed NHL, with an alternative mechanism of action to existing treatments.
Company: the company was in the early development phase of its market access plan for the product in object.
To design a “Roadmap to market access” in the EU-4 documenting P&R requirements, formal steps, tasks & timelines, and investments the company should plan to launch.
- Set-up of internal discussions to understand the company’s perspective on product launch.
- Leverage previous experience on “analogue” projects (i.e. market access planning, launch sequencing, etc.).
- Screen official (i.e. P&R / HTA agency websites) and unofficial sources to understand formal vs. real P&R timelines in the countries in scope.
- Validation of findings with country experts and gathering of additional, “behind the scene” information about
national P&R processes.
The following outputs were produced: a GANTT with a relevant list of activities required to secure efficient market access action plan by country, together with a list of evidences to be submitted at time of the P&R request, methodological requirements for HE analysis conduction and an investment analysis to implement Market Access tasks.